142 related articles for article (PubMed ID: 34617991)
21. Value of combining HPV-DNA testing with follow-up Papanicolaou smear in patients with prior atypical squamous cells of undetermined significance.
Farag R; Redline R; Abdul-Karim FW
Acta Cytol; 2008; 52(3):294-6. PubMed ID: 18540292
[TBL] [Abstract][Full Text] [Related]
22. Improved abnormal Pap smear triage using cervical cancer biomarkers.
Killeen JL; Dye T; Grace C; Hiraoka M
J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
24. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal cytological follow-up of patients with a papanicolaou test interpretation of "atypical squamous cells of undetermined significance" that was followed by a negative reflex test for high-risk human papillomavirus types.
Rodriguez R; Fadare O
Int J Gynecol Pathol; 2008 Jan; 27(1):108-12. PubMed ID: 18156984
[TBL] [Abstract][Full Text] [Related]
26. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
27. Follow up of atypical squamous cell Pap smears in Iraqi women.
Pity IS; Shamdeen MY; Wais SA
Asian Pac J Cancer Prev; 2012; 13(7):3455-60. PubMed ID: 22994777
[TBL] [Abstract][Full Text] [Related]
28. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Woodward L
J Fam Pract; 1998 Feb; 46(2):136-41. PubMed ID: 9487319
[TBL] [Abstract][Full Text] [Related]
30. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
[TBL] [Abstract][Full Text] [Related]
31. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
32. Primary and secondary prevention of cervical cancer among Italian AFAB transgender people.
Lami A; Alvisi S; Siconolfi A; Seracchioli R; Meriggiola MC
Curr Probl Cancer; 2024 Jun; 50():101103. PubMed ID: 38744064
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
Mayrand MH; Duarte-Franco E; Rodrigues I; Walter SD; Hanley J; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
N Engl J Med; 2007 Oct; 357(16):1579-88. PubMed ID: 17942871
[TBL] [Abstract][Full Text] [Related]
34. Cervical Cancer Screening Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs Versus Provider-Administered Pap Tests.
McDowell M; Pardee DJ; Peitzmeier S; Reisner SL; Agénor M; Alizaga N; Bernstein I; Potter J
LGBT Health; 2017 Aug; 4(4):252-259. PubMed ID: 28665783
[TBL] [Abstract][Full Text] [Related]
35. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.
Guo M; Gong Y; Wang J; Dawlett M; Patel S; Liu P; Bevers TB; Sneige N
Cancer Cytopathol; 2013 Feb; 121(2):79-85. PubMed ID: 23225501
[TBL] [Abstract][Full Text] [Related]
36. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
37. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
38. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
Wong AK; Chan RC; Nichols WS; Bose S
Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
[TBL] [Abstract][Full Text] [Related]
39. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
40. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?
Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Borgatta L; Buck H; Kramer L; Rubin R
J Fam Pract; 1998 Feb; 46(2):125-34. PubMed ID: 9487318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
